Using a function-first "scout fragment"-based approach to develop allosteric covalent inhibitors of conformationally dynamic helicase mechanoenzymes
J. R. Ramsey, P. M. M. Shelton, T. K. Heiss, P. D. B. Olinares, L. E. Vostal, H. Soileau, M. Grasso, S. Warrington, S. Adaniya, M. Miller, S. Sun, D. J. Huggins, R. W. Myers, B. T. Chait, E. V. Vinogradova, T. M. Kapoor
Abstract
Helicases, classified into six superfamilies, are mechanoenzymes that utilize energy derived from ATP hydrolysis to remodel DNA and RNA substrates. These enzymes have key roles in diverse cellular processes, such as genome replication and maintenance, ribosome assembly and translation. Helicases with essential functions only in certain cancer cells have been identified and helicases expressed by certain viruses are required for their pathogenicity. As a result, helicases are important targets for chemical probes and therapeutics. However, it has been very challenging to develop selective chemical inhibitors for helicases, enzymes with highly dynamic conformations. We envisioned that electrophilic scout fragments, which have been used for chemical proteomic based profiling, could be leveraged to develop covalent inhibitors of helicases. We adopted a function-first approach, combining enzymatic assays with enantiomeric probe pairs and mass spectrometry, to develop a covalent inhibitor that selectively targets an allosteric site in SARS-CoV-2 nsp13, a superfamily-1 helicase. Further, we demonstrate that scout fragments inhibit the activity of two human superfamily-2 helicases, BLM and WRN, involved in genome maintenance. Together, our findings suggest a covalent inhibitor discovery approach to target helicases and potentially other conformationally dynamic mechanoenzymes.
02 /Specification & Classification
Click any tag to browse matching papers- Organism
- Assay
- Research Focus
- Approach
Reproducibility ledger
Nobody has reported trying to reproduce this paper yet. Did you replicate an experiment or run the code? Your report saves the next lab a week.
Sign in to file a reproducibility report.
Related papers
- Discovery of COVID-19 Inhibitors Targeting the SARS-CoV2 Nsp13 Helicase
M. A. White, W. Lin, X. Cheng·bioRxiv·Aug 9, 2020
- Modelling the active SARS-CoV-2 helicase complex as a basis for structure-based inhibitor design
D. Berta, M. Badaoui, … E. Rosta·bioRxiv·Nov 3, 2020
- Structure, Mechanism and Crystallographic fragment screening of the SARS-CoV-2 NSP13 helicase
J. A. Newman, A. Douangamath, … O. Gileadi·Nature CommunicationsPeer-reviewed·Aug 11, 2021
- Heli-SMACC: Helicase-targeting SMAll Molecule Compound Collection
Holli‐Joi Martin, Mohammad Anwar Hossain, … Alexander Tropsha·bioRxiv·Jul 4, 2024
- Identifying SARS-CoV-2 Antiviral Compounds by Screening for Small Molecule Inhibitors of Nsp13 Helicase
R. Beale, A. P. Bertolin, … J. Zeng·bioRxiv·Apr 7, 2021
- Variable inhibition of unwinding rates of DNA catalyzed by the SARS-Cov-2 (COV19) helicase nsp13 by structurally distinct single DNA lesions.
A. H. Sales, S. Ciervo, … N. E. Geacintov·bioRxiv·Oct 13, 2021